ES2139667T3 - Peptidos sinteticos para el tratamiento de la miastenia gravis. - Google Patents

Peptidos sinteticos para el tratamiento de la miastenia gravis.

Info

Publication number
ES2139667T3
ES2139667T3 ES93916644T ES93916644T ES2139667T3 ES 2139667 T3 ES2139667 T3 ES 2139667T3 ES 93916644 T ES93916644 T ES 93916644T ES 93916644 T ES93916644 T ES 93916644T ES 2139667 T3 ES2139667 T3 ES 2139667T3
Authority
ES
Spain
Prior art keywords
treatment
different
synthetic peptides
peptides
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93916644T
Other languages
English (en)
Inventor
Michael Sela
Edna Mozes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2139667T3 publication Critical patent/ES2139667T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCUBREN PEPTIDOS QUE TIENEN AL MENOS NUEVE RESIDUOS AMINOACIDOS QUE INCLUYEN CADA UNO UNA SECUENCIA AMINOACIDA QUE CORRESPONDE A LA POSICION P200-208 O P262-266 DE LA SUBUNIDAD ALFA RECEPTORA DE ACETILCOLINA HUMANA, PERO QUE DIFIEREN POR UNA O MAS SUSTITUCIONES AMINOACIDAS.ESTOS PEPTIDOS INHIBEN LA RESPUESTA PROLIFERATIVA DE LIMFOCITOS PERIFERICOS DE LA SANGRE HUMANOS A LOS PEPTIDOS MIASTOGENICOS P195-21 Y P259-271 Y SON ADECUADOS PARA EL TRATAMIENTO DE SUJETOS AFECTADOS DE MIASTENIA GRAVIS.
ES93916644T 1992-06-18 1993-06-18 Peptidos sinteticos para el tratamiento de la miastenia gravis. Expired - Lifetime ES2139667T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90039392A 1992-06-18 1992-06-18

Publications (1)

Publication Number Publication Date
ES2139667T3 true ES2139667T3 (es) 2000-02-16

Family

ID=25412446

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93916644T Expired - Lifetime ES2139667T3 (es) 1992-06-18 1993-06-18 Peptidos sinteticos para el tratamiento de la miastenia gravis.

Country Status (11)

Country Link
EP (1) EP0646016B1 (es)
JP (1) JP3996635B2 (es)
AT (1) ATE183652T1 (es)
AU (1) AU678372B2 (es)
CA (1) CA2138258C (es)
DE (1) DE69326145T2 (es)
DK (1) DK0646016T3 (es)
ES (1) ES2139667T3 (es)
GR (1) GR3031371T3 (es)
IL (3) IL122445A0 (es)
WO (1) WO1994000148A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066621A (en) * 1989-12-10 2000-05-23 Yeda Research And Development Co. Ltd. Synthetic peptides for the treatment of myasthenia gravis
US5843462A (en) * 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
WO1999030736A2 (en) 1997-12-16 1999-06-24 Regents Of The University Of Minnesota Methods to treat undesirable immune responses
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
EP4352090A2 (en) 2021-06-07 2024-04-17 Toleranzia AB Fusion protein for treating myasthenia gravis
EP4687970A1 (en) * 2023-03-24 2026-02-11 Cour Pharmaceuticals Development Company Inc. Tolerizing immune modifying nanoparticles for myasthenia gravis treatment

Also Published As

Publication number Publication date
GR3031371T3 (en) 2000-01-31
EP0646016A4 (en) 1995-07-12
CA2138258A1 (en) 1994-01-06
AU678372B2 (en) 1997-05-29
EP0646016A1 (en) 1995-04-05
CA2138258C (en) 2003-08-19
IL122445A (en) 2000-08-31
WO1994000148A1 (en) 1994-01-06
ATE183652T1 (de) 1999-09-15
AU4642993A (en) 1994-01-24
JP3996635B2 (ja) 2007-10-24
DE69326145D1 (de) 1999-09-30
JPH07508521A (ja) 1995-09-21
IL122445A0 (en) 1998-06-15
EP0646016B1 (en) 1999-08-25
IL106065A0 (en) 1993-10-20
IL106065A (en) 1999-10-28
DE69326145T2 (de) 2000-04-27
DK0646016T3 (da) 2000-03-20

Similar Documents

Publication Publication Date Title
ES2038571T1 (es) Procedimiento de preparacion de anticuerpos monoclonales especificos de las interleucinas 1alfa y 1beta.
ES2133271T3 (es) Receptores para factores de crecimiento de fibroblastos.
ATE444360T1 (de) T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe)
ATE307827T1 (de) Respiratorisches syncytialvirus; impfstoffe und diagnostische tests
DK164088A (da) Syntetiske peptidantigener til paavisning af hiv-1-infektion
MX163592B (es) Compuestos de polipeptido que tienen actividad liberadora de la hormona del crecimiento
NO821111L (no) Radioaktivt merkede peptider
DK1082128T3 (da) Lysinholdige peptider til behandling af hjertesygdom
ES2115622T3 (es) Clones moleculares de hiv-1 y usos de los mismos.
ES2139667T3 (es) Peptidos sinteticos para el tratamiento de la miastenia gravis.
DE69109824D1 (de) Verfahren zur Untersuchung des Bewegungssystems des Auges.
SE8403377D0 (sv) Nya peptider
ES2061495T3 (es) Peptidos relacionados con el virus htlv-iii, anticuerpos para los peptidos, vacunas, inmunizacion activa y pasiva contra el virus del sida y prueba diagnostica para la deteccion serologica del virus del sida.
DE69333709D1 (de) T-zell epitope des raygraspollen-allergens
DE69636881D1 (de) Stereoisomere von fettsäureanalogen zur diagnostischen bildgebung
ES2057579T3 (es) Peptidos e1 y c de rubeola.
DK410887D0 (da) Protein isoleret fra pattedyrhjernevaev
DE69607962D1 (de) Synthetische peptide und diese enthaltende pharmazeutische zusammensetzungen
DK0422215T3 (da) Antibakterielle peptider og antimalariapeptider
ATE98962T1 (de) Menschliche rhinoviruspeptide.
FI875325A7 (fi) Näkyvänvalonsäteilyttäjälaite lääketieteelliseen käyttöön.
DE69323688D1 (de) Epitop-Peptide von menschlichem Parvovirus
ES2061908T3 (es) Antagonistas competitivos de gonadoliberina.
EP0697112A4 (en) C-TERMINAL SEQUENCING OF PEPTIDES THAT MAY CONTAIN PROLIN
IT8253834U1 (it) Dispositivo di uso medico chirurgico per la pinzatura graduale temporanea e/o definitiva di vasi e/o tessuti, obliterazione temporanea e/o definitiva tramite graffe di vasi e/o tessuti, taglio parziali e/o netto di vasi e/o tessuti

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 646016

Country of ref document: ES